Sign In
Buy GRTS
$0.0322
+0 (+0%)
At Close: Nov 05, 2024
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
04:05pm, Thursday, 02'nd May 2024
-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to devel
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Thursday, 02'nd May 2024
Gritstone bio (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
07:00am, Monday, 29'th Apr 2024
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced t
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
12:15pm, Saturday, 20'th Apr 2024
NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS). Such investors are advised
-- Paper details vaccine design optimization process of Gritstone's “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoan
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
09:30am, Friday, 12'th Apr 2024
NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS). Such investors are a
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround
10:35am, Monday, 08'th Apr 2024
Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estim
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
12:22am, Sunday, 07'th Apr 2024
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
07:15pm, Thursday, 04'th Apr 2024
NEW YORK , April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS). Such investors are advised
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
02:36pm, Thursday, 04'th Apr 2024
Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.
Why Are Health Insurance Stocks HUM, UNH, CI Down Today?
10:29am, Tuesday, 02'nd Apr 2024
Health insurance stocks are falling on Tuesday after President Joe Biden's Administration announced it won't increase Medicare Advantage rates for 2025. This comes as a surprise to health insurance co
Why Is Gritstone Bio (GRTS) Stock Down 44% Today?
09:16am, Tuesday, 02'nd Apr 2024
Gritstone Bio (NASDAQ: GRTS ) stock is falling on Tuesday after the clinical-stage biotechnology company announced the pricing of an underwritten public offering for its shares. This public offering
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
11:00pm, Monday, 01'st Apr 2024
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced
Gritstone bio Announces Proposed Public Offering
04:10pm, Monday, 01'st Apr 2024
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
04:01pm, Monday, 01'st Apr 2024
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction
